Prostate cancer is projected to be the most commonly diagnosed cancer among men in the United States next year, and the updated PSA testing guidelines for 2026 arrive at a pivotal moment for anyone weighing whether and when to get screened.
The American Cancer Society estimates 333,830 men will be newly diagnosed in 2026, and 36,320 will die from the disease. The American Urological Association (AUA) and Society of Urologic Oncology (SUO) have just released a new amendment that changes how doctors approach early detection of prostate cancer.
Why the New Prostate Cancer Screening Rules Matter Now
Survival depends heavily on when the disease is caught. Five-year relative survival approaches 100 percent for the 84 percent of patients diagnosed with localized or regional disease, but drops to 38 percent for those presenting with distant-stage disease, according to the American Cancer Society’s 2026 Cancer Statistics report.
Race also plays a significant role. Black men face an incidence rate nearly 70 percent higher than that of white men, and they are two to four times more likely to die from prostate cancer than men in other racial and ethnic groups.
“This amendment reflects our continued commitment to ensuring that patients and clinicians have access to the most current, evidence‑based recommendations for early detection of prostate cancer. As the science evolves, so must our guidance. These updates incorporate the latest data to support more personalized, informed, and effective screening and follow‑up strategies for patients at risk,” said Dr. Daniel Lin, chair of the guideline amendment.
What the AUA and SUO Changed in the 2026 Amendment
The new Early Detection of Prostate Cancer Guideline includes 35 recommendations covering PSA screening and biopsy protocols. The panel drew on a systematic review of evidence spanning more than two decades.
The updated framework emphasizes shared decision-making, risk-adapted screening strategies and more selective use of biopsy and adjunctive testing. In practice, that means doctors are expected to talk through a patient’s values, risk factors and preferences before ordering a PSA test rather than treating screening as automatic.
When Should Men Start PSA Testing Under the New Guidance?
The key guideline recommendations lay out clear starting ages based on individual risk.
- Standard-risk men should be offered a baseline PSA test at ages 45 to 50.
- Men at increased risk, including those with Black ancestry, germline mutations or a strong family history, should be offered screening starting at ages 40 to 45.
Once screening begins, regular PSA testing is offered every two to four years for men ages 50 to 69. Intervals may be personalized or discontinued through shared decision-making, weighing factors such as age, PSA level, prostate cancer risk, life expectancy and overall health.
What Doctors Want Patients to Know
Under the 2026 amendment, PSA remains the initial screening test when screening is performed. But the first step is a conversation. Clinicians are expected to engage in shared decision-making with patients for whom screening is appropriate and proceed based on the patient’s values and preferences.
For men with a family history or other elevated risk factors, that discussion should start earlier rather than later. The full guideline is available at AUANet.org/EDPCGuideline2026.
